title: Hysterectomy, endometrial ablation and Mirena® for heavy menstrual bleeding: a systematic review of clinical effectiveness and cost-effectiveness analysis.
abstract: OBJECTIVE
  The aim of this project was to determine the clinical effectiveness and cost-effectiveness of hysterectomy, first- and second-generation endometrial ablation (EA), and Mirena® (Bayer Healthcare Pharmaceuticals, Pittsburgh, PA, USA) for the treatment of heavy menstrual bleeding.
  
  
  METHODS
  Individual patient data (IPD) meta-analysis of existing randomised controlled trials to determine the short- to medium-term effects of hysterectomy, EA and Mirena. A population-based retrospective cohort study based on record linkage to investigate the long-term effects of ablative techniques and hysterectomy in terms of failure rates and complications. Cost-effectiveness analysis of hysterectomy versus first- and second-generation ablative techniques and Mirena.
  
  
  METHODS
  Data from women treated for heavy menstrual bleeding were obtained from national and international trials. Scottish national data were obtained from the Scottish Information Services Division.
  
  
  METHODS
  Women who were undergoing treatment for heavy menstrual bleeding were included.
  
  
  METHODS
  Hysterectomy, first- and second-generation EA, and Mirena.
  
  
  METHODS
  Satisfaction, recurrence of symptoms, further surgery and costs.
  
  
  RESULTS
  Data from randomised trials indicated that at 12 months more women were dissatisfied with first-generation EA than hysterectomy [odds ratio (OR): 2.46, 95% confidence interval (CI) 1.54 to 3.93; p = 0.0002), but hospital stay [WMD (weighted mean difference) 3.0 days, 95% CI 2.9 to 3.1 days; p < 0.00001] and time to resumption of normal activities (WMD 5.2 days, 95% CI 4.7 to 5.7 days; p < 0.00001) were longer for hysterectomy. Unsatisfactory outcomes associated with first- and second-generation techniques were comparable [12.2% (123/1006) vs 10.6% (110/1034); OR 1.20, 95% CI 0.88 to 1.62; p = 0.2). Rates of dissatisfaction with Mirena and second-generation EA were similar [18.1% (17/94) vs 22.5% (23/102); OR 0.76, 95% CI 0.38 to 1.53; p = 0.4]. Indirect estimates suggested that hysterectomy was also preferable to second-generation EA (OR 2.32, 95% CI 1.27 to 4.24; p = 0.006) in terms of patient dissatisfaction. The evidence to suggest that hysterectomy is preferable to Mirena was weaker (OR 2.22, 95% CI 0.94 to 5.29; p = 0.07). In women treated by EA or hysterectomy and followed up for a median [interquartile range (IQR)] duration of 6.2 (2.7-10.8) and 11.6 (7.9-14.8) years, respectively, 962/11,299 (8.5%) women originally treated by EA underwent further gynaecological surgery. While the risk of adnexal surgery was similar in both groups [adjusted hazards ratio 0.80 (95% CI 0.56 to 1.15)], women who had undergone ablation were less likely to need pelvic floor repair [adjusted hazards ratio 0.62 (95% CI 0.50 to 0.77)] and tension-free vaginal tape surgery for stress urinary incontinence [adjusted hazards ratio 0.55 (95% CI 0.41 to 0.74)]. Abdominal hysterectomy led to a lower chance of pelvic floor repair surgery [hazards ratio 0.54 (95% CI 0.45 to 0.64)] than vaginal hysterectomy. The incidence of endometrial cancer following EA was 0.02%. Hysterectomy was the most cost-effective treatment. It dominated first-generation EA and, although more expensive, produced more quality-adjusted life-years (QALYs) than second-generation EA and Mirena. The incremental cost-effectiveness ratios for hysterectomy compared with Mirena and hysterectomy compared with second-generation ablation were £1440 per additional QALY and £970 per additional QALY, respectively.
  
  
  CONCLUSIONS
  Despite longer hospital stay and time to resumption of normal activities, more women were satisfied after hysterectomy than after EA. The few data available suggest that Mirena is potentially cheaper and more effective than first-generation ablation techniques, with rates of satisfaction that are similar to second-generation techniques. Owing to a paucity of trials, there is limited evidence to suggest that hysterectomy is preferable to Mirena. The risk of pelvic floor surgery is higher in women treated by hysterectomy than by ablation. Although the most cost-effective strategy, hysterectomy may not be considered an initial option owing to its invasive nature and higher risk of complications. Future research should focus on evaluation of the clinical effectivesness and cost-effectiveness of the best second-generation EA technique under local anaesthetic versus Mirena and types of hysterectomy such as laparoscopic supracervical hysterectomy versus conventional hysterectomy and second-generation EA.
  
  
  BACKGROUND
  The National Institute for Health Research Health Technology Assessment programme.
authors.affiliation: University of Aberdeen, Aberdeen, UK.
authors.forename: S
authors.initials: S
authors.lastname: Bhattacharya
authors.forename: L J
authors.initials: LJ
authors.lastname: Middleton
authors.forename: A
authors.initials: A
authors.lastname: Tsourapas
authors.forename: A J
authors.initials: AJ
authors.lastname: Lee
authors.forename: R
authors.initials: R
authors.lastname: Champaneria
authors.forename: J P
authors.initials: JP
authors.lastname: Daniels
authors.forename: T
authors.initials: T
authors.lastname: Roberts
authors.forename: N H
authors.initials: NH
authors.lastname: Hilken
authors.forename: P
authors.initials: P
authors.lastname: Barton
authors.forename: R
authors.initials: R
authors.lastname: Gray
authors.forename: K S
authors.initials: KS
authors.lastname: Khan
authors.forename: P
authors.initials: P
authors.lastname: Chien
authors.forename: P
authors.initials: P
authors.lastname: O'Donovan
authors.forename: K G
authors.initials: KG
authors.lastname: Cooper
authors.forename: J
authors.initials: J
authors.lastname: Abbott
authors.forename: J
authors.initials: J
authors.lastname: Barrington
authors.forename: S
authors.initials: S
authors.lastname: Bhattacharya
authors.forename: M Y
authors.initials: MY
authors.lastname: Bongers
authors.forename: J-L
authors.initials: JL
authors.lastname: Brun
authors.forename: R
authors.initials: R
authors.lastname: Busfield
authors.forename: T J
authors.initials: TJ
authors.lastname: Clark
authors.forename: J
authors.initials: J
authors.lastname: Cooper
authors.forename: K G
authors.initials: KG
authors.lastname: Cooper
authors.forename: S L
authors.initials: SL
authors.lastname: Corson
authors.forename: K
authors.initials: K
authors.lastname: Dickersin
authors.forename: N
authors.initials: N
authors.lastname: Dwyer
authors.forename: M
authors.initials: M
authors.lastname: Gannon
authors.forename: J
authors.initials: J
authors.lastname: Hawe
authors.forename: R
authors.initials: R
authors.lastname: Hurskainen
authors.forename: W R
authors.initials: WR
authors.lastname: Meyer
authors.forename: H
authors.initials: H
authors.lastname: O'Connor
authors.forename: S
authors.initials: S
authors.lastname: Pinion
authors.forename: A M
authors.initials: AM
authors.lastname: Sambrook
authors.forename: W H
authors.initials: WH
authors.lastname: Tam
authors.forename: I A A
authors.initials: IA
authors.lastname: van Zon-Rabelink
authors.forename: E
authors.initials: E
authors.lastname: Zupi
mesh_terms: D003271:Contraceptive Agents, Female / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D055356:Endometrial Ablation Techniques / Q000009:adverse effects / Q000191:economics / Q000379:methods*; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000009:adverse effects / Q000191:economics / Q000379:methods*; D016912:Levonorgestrel / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D008595:Menorrhagia / Q000188:drug therapy* / Q000191:economics / Q000601:surgery*; D017060:Patient Satisfaction; D011183:Postoperative Complications / Q000453:epidemiology; D019057:Quality-Adjusted Life Years; D013995:Time; D016896:Treatment Outcome
chemical_list: D003271:Contraceptive Agents, Female; D016912:Levonorgestrel